$8.89
+0.48 (+5.71%)
Open$8.57
Previous Close$8.41
Day High$8.97
Day Low$8.35
52W High$38.21
52W Low$20.87
Volume—
Avg Volume197.0K
Market Cap227.72M
P/E Ratio25.21
EPS$1.04
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+208.2% upside
Current
$8.89
$8.89
Target
$27.40
$27.40
$23.46
$27.40 avg
$40.51
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 66.09M | 69.56M | 73.83M |
| Net Income | 7.65M | 9.76M | 11.38M |
| Profit Margin | 11.6% | 14.0% | 15.4% |
| EBITDA | 12.79M | 14.57M | 15.15M |
| Free Cash Flow | 6.98M | 8.54M | 10.02M |
| Rev Growth | +12.3% | +24.1% | -0.1% |
| Debt/Equity | 0.76 | 0.65 | 0.75 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |